Cardio-oncology & otherCohort study
Association of myocardial injury with adverse long-term survival among cancer patients
- Observational cohort study
- NHANES 1999-2004 linked with mortality data
- weighted
Authors' conclusion
As a marker for myocardial injury, hs-cTns were independently associated with worse long-term survival among cancer patients with a stronger relationship with all-cause, cardiovascular, and cancer mortalities using hs-cTn I Ortho assay.
Study context
- Population
- Respondents reporting a cancer diagnosis by a healthcare professional, NHANES 1999–2004weighted
- Participants
- 16,225,560 respondents
- Exposure
- Myocardial injury vs no myocardial injury
- Outcome
- Long-term survival (all-cause, CV and cancer mortality)
Main finding
As reported in the abstract
All-cause mortality
Myocardial injury vs No myocardial injuryaHRP value
all-cause mortality
2.10(95% CI 2.09–2.10)
P < 0.001CV mortality
2.23(CI 2.22–2.24)
P < 0.001cancer mortality
1.59(95% CI 1.59–1.60)
P < 0.001Observational data: associations, not effects.
Further findings
Survival · 5, 10 and 15 years
5 years
10 years
15 years
| Outcome | aHR (95% CI) | P value | |
|---|---|---|---|
| Mortality by hs-cTn I Ortho assay (no pre-existing CVD, subgroup) — hs-cTn I Ortho vs No myocardial injury · all-cause mortality | 6.29 (6.25–6.33) | P < 0.001 | |
| Mortality by hs-cTn I Ortho assay (no pre-existing CVD, subgroup) — hs-cTn I Ortho vs No myocardial injury · CVD mortality | 11.38 (11.23–11.54) | P < 0.001 | |
| Mortality by hs-cTn I Ortho assay (no pre-existing CVD, subgroup) — hs-cTn I Ortho vs No myocardial injury · cancer mortality | 5.02 (4.96–5.07) | P < 0.001 | |
| 0.050.21520Adjusted hazard ratio (log scale) |
Original publication
Association of myocardial injury with adverse long-term survival among cancer patients. Eur J Prev Cardiol. Published 21 March 2024. doi:10.1093/eurjpc/zwae116
Summarised from the published abstract; every number is checked against it